FDA clears Aperio breast tissue image analysis app

Michael Bassett | | Health Imaging | Diagnostic Imaging
Aperio Technologies has received clearance from the FDA to market its IHC HER2 breast tissue image analysis application.

According to the Vista, Calif.-based company, the IHC HER2 breast tissue image analysis application is intended to be used as an aid to the pathologist and accessory to the Dako HerceptTest to help in the detection and semi-quantitative measurement of HER2/new in formalin-fixed, paraffin-embedded normal and neoplastic tissue.

The application is indicated for use as an aid in the assessment of breast cancer patients for whom Herceptin treatment is being considered and can be tuned to accommodate a laboratory’s staining process.

Michael Bassett,

Contributor

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.